This activity is specifically designed for:
Key Stakeholders
Country Program Managers
Decision Makers
Implementing Partners
At the end of the course, learners should be able to:
Share the most recent global guidance related to TB LAM testing
Describe the status of TB and TB LAM testing in the Asia Pacific Region
Identify current barriers and gaps related to TB LAM testing
Propose and facilitate for implementation of TB LAM testing
Actual progress in uptake of TB LF LAM testing has been slow. In 2018, an MSF Access Campaign press release announced that, while 30 countries had procured TB LF LAM tests, only 3 had scaled-up nationally. Reported implementation barriers have included decreased support for CD4 testing, whether the ‘ownership’ of TB LAM testing is by the HIV or TB programs, and insufficient training and implementation guidance. To help address these barriers, this activity addresses the following:
WHO TB LAM guidelines
From guidelines to reality of TB LAM in the Indian health system
TB LAM: A community perspective from Asia
DSD in Thailand: Opportunities for integration of TB LAM testing
TB LAM implementation considerations
Panel discussion: Addressing uptake barriers to TB LF LAM in the APAC region and discussing the way forward
Teri Roberts, Chief of Innovations and Access, The Global Health Impact Group
Patricia Hall, Lead, TB and Clinical Monitoring Team, International Laboratory Branch, Division of Global HIV and TB Center for Global Health, CDC
Lucica Ditiu, Executive Director, Stop TB Partnership
Nazir Ahmed Ismail, Team Lead, WHO Global TB Programme
Leena Menghan, Regional Head, South Asia, MSF Access Campaign
Meirinda Sebayang, Chair, JIP (Jaringan Indonesia Positif)
Reshmie Ramautarsing, Technical Director, Institute of HIV Research and Innovation (IHRI) in Bangkok
N. Kumarasamy, Chief & Director, VHS Infectious Diseases Medical Centre, Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site, India
Add your email to the mailing list to get the latest updates.
